Gammaglobulina subcutánea en inmunodeficiencia común variable. Primera experiencia en España

Hernando, M. Maroto; Palacín, Pere Soler; Nalda, Andrea Martín; Arenas, Monica; Borén, Tora; Nadal, C. Figueras

doi:10.1016/j.anpedi.2008.11.014

Cited by 13 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The benefits of home-based SCIG therapy are reflected in improved health-related quality of life (QoL) and treatment satisfaction reported by children and adults who have switched to SCIG from previous IVIG therapy in hospitals [16,18,19]. Moreover, several studies worldwide have shown that SCIG has similar efficacy to IVIG in preventing infections in PID patients [5,12,13,15,[20][21][22][23].…”

Section: Introductionmentioning

confidence: 99%

Comparative Study of Subcutaneous Versus Intravenous IgG Replacement Therapy in Pediatric Patients with Primary Immunodeficiency Diseases: A Multicenter Study in Argentina

et al. 2013

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Comparative Study of Subcutaneous Versus Intravenous IgG Replacement Therapy in Pediatric Patients with Primary Immunodeficiency Diseases: A Multicenter Study in Argentina

et al. 2013

View full text Add to dashboard Cite

show abstract

Home-Based Subcutaneous Immunoglobulin Versus Hospital-Based Intravenous Immunoglobulin in Treatment of Primary Antibody Deficiencies: Systematic Review and Meta Analysis

et al. 2012

View full text Add to dashboard Cite

Dosing and Therapy Utilization: A Discussion of Updates on PI Treatment Guidelines

Ballow

2012

J Clin Immunol

View full text Add to dashboard Cite

Treatment decisions made in clinical practice, based on current guidelines, often conflict with decisions by third-party payors that restrict the ability of patients with primary immunodeficiency disease (PI) to adhere to appropriate treatment. This is seen by many physicians as potentially placing the health of patients at risk. Key treatment decisions challenged by third-party payors and discussed here include dosing, product safety, and routes of administration. Data on safety issues emphasize that IgG products are not generic drugs and each of the products currently licensed by the Food and Drug Administration (FDA) must be regarded as an individual therapy, given the products' different manufacturing processes and stabilizing ingredients. The issue of switching patients to a different product needs careful consideration as evidence shows that infusion-related adverse events in many patients are frequently related to this activity. Decisions regarding the route of therapy should also be individualized to the patient, weighing such factors as side effects, adherence with therapy, and lifestyle.

show abstract

Gammaglobulina subcutánea en inmunodeficiencia común variable. Primera experiencia en España

Cited by 13 publications

References 21 publications

Comparative Study of Subcutaneous Versus Intravenous IgG Replacement Therapy in Pediatric Patients with Primary Immunodeficiency Diseases: A Multicenter Study in Argentina

Comparative Study of Subcutaneous Versus Intravenous IgG Replacement Therapy in Pediatric Patients with Primary Immunodeficiency Diseases: A Multicenter Study in Argentina

Home-Based Subcutaneous Immunoglobulin Versus Hospital-Based Intravenous Immunoglobulin in Treatment of Primary Antibody Deficiencies: Systematic Review and Meta Analysis

Dosing and Therapy Utilization: A Discussion of Updates on PI Treatment Guidelines

Contact Info

Product

Resources

About